Truist Financial Raises Humana (NYSE:HUM) Price Target to $290.00

Humana (NYSE:HUM) had its target price lifted by Truist Financial from $260.00 to $290.00 in a research report released on Monday morning,Benzinga reports. They currently have a hold rating on the insurance provider’s stock.

Other research analysts have also recently issued research reports about the stock. Cantor Fitzgerald restated a “neutral” rating and set a $395.00 target price on shares of Humana in a research note on Tuesday, October 1st. Morgan Stanley upped their price objective on Humana from $288.00 to $301.00 and gave the stock an “equal weight” rating in a research note on Tuesday, December 17th. Sanford C. Bernstein raised Humana from a “market perform” rating to an “outperform” rating and set a $308.00 price target on the stock in a report on Tuesday, October 8th. Oppenheimer cut their price objective on shares of Humana from $400.00 to $280.00 and set an “outperform” rating for the company in a report on Thursday, October 3rd. Finally, Leerink Partners downgraded shares of Humana from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $400.00 to $250.00 in a report on Wednesday, October 2nd. Twenty investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $302.00.

Humana Price Performance

NYSE HUM opened at $268.22 on Monday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.76 and a current ratio of 1.76. The business’s fifty day moving average is $272.86 and its 200 day moving average is $311.86. The company has a market capitalization of $32.30 billion, a PE ratio of 23.76, a price-to-earnings-growth ratio of 2.12 and a beta of 0.55. Humana has a fifty-two week low of $213.31 and a fifty-two week high of $462.08.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.48 by $0.68. Humana had a return on equity of 13.20% and a net margin of 1.18%. The company had revenue of $29.30 billion during the quarter, compared to the consensus estimate of $28.66 billion. Sell-side analysts predict that Humana will post 16.14 earnings per share for the current year.

Humana Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be issued a $0.885 dividend. The ex-dividend date of this dividend is Tuesday, December 31st. This represents a $3.54 annualized dividend and a dividend yield of 1.32%. Humana’s payout ratio is currently 31.36%.

Insider Buying and Selling at Humana

In other Humana news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the transaction, the insider now directly owns 8,181 shares of the company’s stock, valued at approximately $2,096,463.06. The trade was a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.32% of the company’s stock.

Institutional Investors Weigh In On Humana

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Creative Financial Designs Inc. ADV grew its holdings in shares of Humana by 244.0% during the third quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock valued at $27,000 after buying an additional 61 shares during the last quarter. Atwood & Palmer Inc. purchased a new stake in shares of Humana in the third quarter valued at approximately $29,000. Ashton Thomas Securities LLC purchased a new stake in Humana in the 3rd quarter worth $31,000. Your Advocates Ltd. LLP raised its position in shares of Humana by 81.8% during the 3rd quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock worth $32,000 after purchasing an additional 45 shares during the last quarter. Finally, Hollencrest Capital Management acquired a new position in shares of Humana during the second quarter valued at approximately $40,000. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.